Effect of prophylactic HPV-vaccination (Gardasil®) on recurrent respiratory papillomatosis
Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S209-S210
DOI: 10.1055/s-0044-1784680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Jennifer Sieg und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Since 2007, the Standing Committee on Vaccination (STIKO) has recommended prophylactic vaccination to prevent human papillomavirus (HPV) infection. Possible therapeutic benefits are discussed. In this study, the effect of vaccination on the course of recurrent respiratory papillomatosis (RRP) is examined.
Methods
Files of 63 RRP patients (21 females, 43 males) treated at the Kiel ENT Clinic from 2008 to 2021 were retrospectively reviewed. The burden of disease was defined by ablations per year and the summed anatomical Derkay score related to the treatment period in years (Derkay Summe ).
Results
18/63 patients (28.6%; 10 females, 8 males) were vaccinated against HPV. All vaccination time points were available in 10 patients (55.6%). Considering vaccination data with the maximum observation period for each patient, ablations per year significantly decreased from a median of 1.72 to 0.33 (p 0.05).
Discussion
HPV vaccination in RRP is significantly associated with a reduction in disease burden, demonstrated by decreased ablations and reduced tumor spread, as measured by the anatomical Derkay score. This should be further examined in larger groups to determine whether HPV vaccination for RRP should be standardized as a therapeutic option, even in the early stages. In addition, the therapeutic effect of vaccination should be investigated for other HPV-associated lesions. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Sieg, J., Fazel, A., Quabius, E. S., Dempfle, A., & Hoffmann, M. (2024). Effect of prophylactic HPV-vaccination (Gardasil®) on recurrent respiratory papillomatosis. Laryngo-Rhino-Otologie, 103(S 02 S 02), S209-S210. https://doi.org/10.1055/s-0044-1784680
Vancouver
Sieg J, Fazel A, Quabius ES, Dempfle A, Hoffmann M. Effect of prophylactic HPV-vaccination (Gardasil®) on recurrent respiratory papillomatosis. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S209-S210. doi:10.1055/s-0044-1784680
BibTeX
@article{Sieg2024,
author = {Sieg, Jennifer and Fazel, Asita and Quabius, Elgar Susanne and Dempfle, Astrid and Hoffmann, Markus},
title = {Effect of prophylactic HPV-vaccination (Gardasil®) on recurrent respiratory papillomatosis},
journal = {Laryngo-Rhino-Otologie},
year = {2024},
volume = {103},
number = {S 02 S 02},
pages = {S209--S210},
doi = {10.1055/s-0044-1784680}
}
EUVIMED